**5. Conclusions**

Combining bone graft and metallic augments in severe glenoid bone loss during RSA is safe and effective, resulting in significantly improved clinical outcomes and ROM. In cases of severe glenoid bone loss where bone graft alone may be insufficient, a combination of bone graft and metallic augments should be considered.

**Author Contributions:** M.N.: data curation and writing—original draft preparation; L.N.: data curation, supervision, and writing—review and editing; H.B.: methodology, statistics, and writing— review and editing; S.W.L.H.: methodology and writing—review and editing; S.W.: data curation and visualization; X.L.C.: methodology and writing—review and editing; A.L.: conceptualization; methodology, supervision, resources, funding acquisition and writing—review and editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by FORE (Foundation for Research and Teaching in Orthopaedics, Sports Medicine, Trauma and Imaging in the Musculoskeletal System); gran<sup>t</sup> number FORE 2021-35.

**Institutional Review Board Statement:** The study received ethics committee approval from both centers (CCER 14-227 and COS-RGDS-2021-06-009-NEYTON-L).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** All data relevant to the study are included in the article. Details regarding where data supporting reported results can be asked at the following e-mail address: hugo.bothorel@latour.ch.

**Conflicts of Interest:** Marko Nabergoj reports no conflict of interest. Lionel Neyton reports that he is a paid consultant for Arthrex and Tornier/Stryker and receives royalties from Tornier/Stryker. He is member of the Advisory Board of Sparta Biopharma and owns stock options. Hugo Bothorel reports no conflict of interest. Sean WL Ho reports no conflict of interest. Sidi Wang reports no conflict of interest. Xueling Chong reports no conflict of interest. Dr. Lädermann reports that he is a paid consultant for Arthrex, Inc., Stryker, and Medacta, and he receives royalties from Stryker. He is the founder of the FORE Foundation, Med4cast, and BeeMed. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
